WGS GeneDx Holdings Corp.

NASDAQ
$78.08

GeneDx Holdings Corp. (WGS) is expected to report earnings on November 2, 2026, after the market close. The consensus earnings estimate is a loss of $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.7% since its last earnings release on August 3, 2026.

GeneDx Holdings Beat Consensus Estimates, Reaffirms
Monday, August 3, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.15)
Rev est $124.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $74.64

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About GeneDx Holdings Corp.

GeneDx delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery.

Sector

Healthcare

Industry

Medical Labs & Research